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Available online 27 December 2005Parkinson disease (PD) and dementia with Lewy bodies (DLB) are
characterized by the accumulation of abnormal a-synuclein and
ubiquitin in protein aggregates conforming Lewy bodies and Lewy
neurites. Ubiquitin C-terminal hydrolase-1 (UCHL-1) disassembles
polyubiquitin chains to increase the availability of free monomeric
ubiquitin to the ubiquitin proteasome system (UPS) thus favoring
protein degradation. Since mutations in the UCHL-1 gene, reducing
UPS activity by 50%, have been reported in autosomal dominant PD,
and UCHL-1 inhibition results in the formation of a-synuclein
aggregates in mesencephalic cultured neurons, the present study was
initiated to test UCHL-1 mRNA and protein levels in post-mortem
frontal cortex (area 8) of PD and DLB cases, compared with age-
matched controls. TaqMan PCR assays, and Western blots demon-
strated down-regulation of UCHL-1 mRNA and UCHL-1 protein in the
cerebral cortex in DLB (either in pure forms, not associated with
Alzheimer disease: AD, and in common forms, with accompanying AD
changes), but not in PD, when compared with age-matched controls.
Interestingly, UCHL-1 mRNA and protein expressions were reduced in
the medulla oblongata in the same PD cases. Moreover, UCHL-1
protein was decreased in the substantia nigra in cases with Lewy body
pathology. UCHL-1 down-regulation was not associated with reduced
protein levels of several proteasomal subunits, including 20SX, 20SY,
19S and 11Sa. Yet UCHL-3 expression was reduced in the cerebral
cortex of PD and DLB patients. Together, these observations show
reduced UCHL-1 expression as a contributory factor in the abnormal
protein aggregation in DLB, and points UCHL-1 as a putative
therapeutic target in the treatment of DLB.
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Parkinson’s disease (PD) and Dementia with Lewy bodies
(DLB) are considered a-synucleinopathies because abnormal a-
synuclein is aggregated into Lewy bodies and Lewy neurites in
selected nuclei of the brain stem, spinal cord, autonomic ganglia. In
addition, DLB is characterized by the widespread distribution of
LBs and a-synuclein-containing neurites in the cerebral cortex
(Forno, 1996; Spillantini et al., 1998; Ince et al., 1998; Jellinger
and Mizuno, 2003; Ince and McKeith, 2003). DLB is often
accompanied by Alzheimer’s disease (AD) and this is considered
the common form (DLBc); DLB with minimal hA4-amyloid
deposits and no tau pathology characterizes the pure form (DLBp)
(Kosaka, 1990, 1993). The reasons of abnormal a-synuclein
accumulation in neurons and neuronal processes in Lewy body
diseases are not known but several observations, point to the
likelihood that the ubiquitin–proteasome system (UPS) is involved
in the pathogenesis of PD and DLB (McNaught and Olanow, 2003;
McNaught et al., 2003).
The UPS regulates intracellular protein turnover, and the
elimination of misfolded, mutated and damaged proteins
(Herschko and Ciechanover, 1998; Glickman and Ciechanover,
2002). The process is initiated with the conjugation of the target
protein to a chain of ubiquitin molecules to be recognized by the
26S proteasome which is composed of the 20S proteasome and the
19S, or PA700, complex. The 20S proteasome contains a 28-
subunit catalytic core formed by two outer rings (each with 7 a-
subunits) and two inner rings (X, Y, each with 7 h-subunits),
forming a cylindrical structure. The 19S complex recognizes
ubiquitinylated proteins tagged for destruction, and unfolds and
inserts the proteins into the core of the 20S proteasome where they
are degraded (Tanaka and Tsurumi, 1997; Ciechanover, 1998;
Botchler et al., 1999). In addition to the 19S complex, the 20S
proteasome can interact with the 11S activator, or PA28ah
complex, forming the PA28 proteasome (Groetrup et al., 1996;
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(UCHL-1) belongs to a family of enzymes that disassembles
polyubiquitin chains to increase the availability of free monomeric
ubiquitin to the UPS (Larsen et al., 1996, 1998). Yet UCHL-1 has
two opposing enzymatic capacities as ubiquityl ligase activity has
been demonstrated in addition to the hydrolase activity (Liu et al.,
2002). UCHL-1 is one of the most abundant proteins in the brain,
representing 1–2% of total soluble brain protein (Wilkinson et al.,
1989; Solano et al., 2000).
The implications of UCHL-1 in PD are derived from the
discovery of the I93M mutation in the UCHL-1 gene in a German
family with autosomal dominant PD (Leroy et al., 1998). This
mutation leads to 50% reduction in the catalytic UPS activity in
vitro (Lansbury and Brice, 2002). In contrast, the polymorphism
Ser18Tyr in UCHL-1 is associated with a significant lower risk of
suffering PD (Maraganore et al., 1999, 2004). Interestingly,
Ser18Tyr polymorphism results in selective reduction of ligase
activity with preserved hydrolase activity (Liu et al., 2002). Finally,
inhibition of UCHL-1 in fetal rat ventral mesencephalic cultures is
accompanied by the production of a-synuclein aggregates
(McNaught et al., 2002a). Recent neuropathological studies have
shown classical Lewy pathology and co-aggregation of a-
synuclein and UCHL-1 in cortical neurons in a deceased sibling
of the family affected with the I93M a-synuclein mutation who
developed, in addition to DOPA-responsive parkinsonism, marked
cognitive deficits (Auburger et al., 2005).
These findings prompted the examination of UCHL-1 mRNA
by TaqMan PCR assay, and UCHL-1 protein levels by Western
blotting, in the frontal cortex of PD, DLBp, DLBc, and age-
matched controls, obtained with short post-mortem delays.
Accompanying determinations of UCHL-1 were carried out in
other brain regions as the medulla oblongata and substantia nigra.
The present study shows UCHL-1 down-regulation, accompanied
by normal expression of several subunits of the 19S, 11S and 20S
proteasome, in the frontal cortex in DLB, and points low UCHL-1
expression as a determining factor of the abnormal a-synuclein
accumulation in DLB.Material and methods
Brain samples
The brains of six patients with PD, seven DLBp, six DLBc, and
six aged-matched controls were obtained at autopsy, following
informed consent of the patients or their relatives and the approval
of the local Ethics Committee. Both genders were represented
equally; age range was between 60 and 91 years (mean age 72
years), the average time between death and tissue processing was
8 h. Half of the brain was immediately cut on coronal sections, 1
cm thick, frozen on dry ice and stored at 80-C until use. In
addition, samples 2 mm thick of the cerebral isocortex, cingulum,
hippocampus and entorhinal cortex, and brain stem were fixed with
4% paraformaldehyde for 24 h, cryoprotected with 30% saccha-
rose, frozen on dry ice and stored at 80-C until use. For
morphological examinations, the brains were fixed by immersion
in 10% buffered formalin for 2 or 3 weeks. The neuropathological
study was carried out on de-waxed 4-Am-thick paraffin sections of
the frontal (area 8), primary motor, primary sensory, parietal,
temporal superior, temporal inferior, anterior cingulated, anterior
insular, and primary and associative visual cortices; entorhinalcortex and hippocampus; caudate, putamen and pallidum; medial
and posterior thalamus; subthalamus; Meynert nucleus; amygdala;
midbrain (two levels), pons and medulla oblongata; and cerebellar
cortex and dentate nucleus. The sections were stained with
hematoxylin and eosin, luxol fast blue-Klu¨ver Barrera, and for
immunohistochemistry to glial fibrillary acidic protein, CD68 and
Licopericum esculentum lectin for microglia, hA4 amyloid, pan-
tau, phosphorylation-specific tau Thr181, Ser202, Ser214, Ser262,
Ser396 and Ser422, and aB-crystallin, a-synuclein and ubiquitin.
Neuropathological characterization of PD was accordingly to
well-established neuropathological criteria (Jellinger and Mizuno,
2003). Neuropathological characterization of DLB was according
to consensus guidelines of the consortium on DLB international
workshop (McKeith et al., 1996, 2000). Associated AD stages
were further established depending on the amyloid deposition
burden and neurofibrillary pathology following the nomenclature
of Braak and Braak (1999). Stages of amyloid deposition refer to
initial deposits in the basal neocortex (stage A), deposits extended
to the association areas of the neocortex (stage B), and heavy
deposition throughout the entire cortex (stage C). Stages of
neurofibrillary pathology correspond to transentorhinal (I– II),
limbic (III–IV) and neocortical (V and VI). To further refine a-
synuclein pathology, staging of brain pathology related to sporadic
PD proposed by Braak et al. was used in the present study.
Basically, stages 1 and 2 affect the medulla oblongata plus the
pontine tegmentum; stage 3, the midbrain; stage 4, the basal
prosencephalon and mesocortex; and stages 5 and 6, the neocortex
(Braak et al., 2003). Clinically, all cases of PD had suffered from
classical PD lasting from 8 to 15 years, and none of them had
cognitive impairment. Cases with DLB fulfilled the clinical criteria
proposed by the consortium on DLB international workshop
(McKeith et al., 1996, 2000). Control cases were considered in
the absence of neurological symptoms and signs, and no
abnormalities in the neuropathological study. The main neuropath-
ological data in the present series are summarized in Table 1.
Further details in DLB cases can be found elsewhere (Dalfo´ et al.,
2004).
Biochemical studies were carried out in frozen samples of the
frontal cortex (area 8) in DLB, in the cerebral cortex and medulla
oblongata in PD, and in the substantia nigra in DLB and PD.
Control and diseased brains were processed in parallel.
In addition, samples of the frontal cortex from one control
individual were obtained at 3 h post-mortem and immediately
frozen (time 0), or stored at 4-C for 3 h, 6 h, 22 h and 48 h, and
then frozen to mimic variable post-mortem delay in tissue
processing.
mRNA isolation
mRNA isolation was carried out in two steps. Total RNA was
isolated using TRizol Reagent (Life Technologies) followed by the
RNeasy Protect Mini Kit (Qiagen). Frozen human brain tissues
were directly homogenized in 1 ml of TRizol reagent per 100 mg
tissue, and total RNA was extracted following the protocol
suggested by the supplier. Purified total RNA was re-suspended
in 100 Al of RNase-free water, and mRNA purification was
obtained following the protocol provided with the RNeasy Protect
Mini Kit with minor modifications; DNase I treatment was
discarded due to the elimination of genomic DNA during TRizol
extraction. The concentration of each sample was obtained from
A260 measurements. For transcriptomic purposes, RNA samples
Table 1
Summary of the main clinical and neuropathological findings in the present series
Case Disease Gender Age (year) Post-mortem (h) Braak stages AD Braak stages PD
hA4 amyloid NFT
1 Control M 63 17 0 0 0
2 Control M 70 13 0 0 0
3 Control M 79 7 0 II 0
4 Control F 65 4 0 I 0
5 Control F 80 11 0 I 0
6 Control F 82 11 A III 0
7 PD M 66 5 0 I 3
8 PD M 81 5 A II 4
9 PD M 88 2 0 II 4
10 PD M 70 9 0 0 4
11 PD F 60 4 A 0 4
12 PD F 70 4 0 0 4
13 DLBp M 60 8 A I 6
14 DLBp M 68 12 B 0 6
15 DLBp M 71 6 B 0 5
16 DLBp M 81 16 A I 6
17 DLBp M 85 7 B II 6
18 DLBp F 70 8 0 0 5
19 DLBp F 77 5 B 0 5
20 DLBc M 78 6 C V 6
21 DLBc M 78 7 C V 6
22 DLBc F 71 5 C V 5
23 DLBc F 78 7 C VI 6
24 DLBc F 78 13 C IV 5
25 DLBc F 91 5 C V 6
Parkinson’s disease (PD), Diffuse Lewy body disease: Dementia with Lewy bodies, pure form (DLBp) and common form (DLBc), and controls. M: male, F:
female. NFT: neurofibrillary tangle. Braak stages refers to Braak and Braak Alzheimer’s disease (AD) changes (Braak and Braak, 1999). Staging of a-
synuclein pathology (Lewy bodies and Lewy neurites) related to sporadic Parkinson’s disease (PD) was according to Braak et al. (2003).
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The Bioanalyzer calculates fragment size and sample concentra-
tion, and the ratio of the surface below the 18S and 28S peaks was
used for determination of RNA quality.
cDNA synthesis and TaqMan PCR
For each 10 Al reverse transcription reaction, 200 ng human
RNA (in 3.85 Al water) was mixed with 2.5 AM oligodT primer,
1 TaqMan RT buffer, 5.5 mM MgCl2, 500 AM each of dATP,
dTTP, dCTP and dGTP, 0.08 U RNase inhibitor and 0.31 U
MultiScribe Reverse Transcriptase (Applied Biosystems). Reac-
tions were carried out at 25-C for 10 min to maximize primer-RNA
template binding, followed by 30 min at 48-C, and then by
incubation for 5 min at 95-C to deactivate reverse transcriptase.
Parallel reactions for each RNA sample were run in the absence of
MultiScribe Reverse transcriptase to assess the degree of contam-
inating genomic DNA.
The TaqMan probe (Applied Biosystems) anneals to one strand
of the DNA template between forward and reverse PCR primers. It
contains a reporter dye which is released by Taq polymerase during
the amplification step, with the fluorescence originated being
proportional to the amount of product accumulated.
Primers and fluorescence probes specific for human UCHL-1
and h-actin were purchased from TaqMan* Gene Expression
Assays (Applied Biosystems). Human h-actin was used as
endogenous references.
TaqMan PCR assays for UCHL-1 and endogenous reference h-
actin were performed in triplicate on cDNA samples in 96-welloptical plates on an ABI Prism 7700 Sequence Detection system
(PE Applied Biosystems). The plate was capped using optical caps
(Applied Biosystems). For each 20 Al TaqMan reaction, 9 Al cDNA
(diluted 1/50, which corresponds approximately to cDNA from 4
ng of RNA) was mixed with 1 Al 20 TaqMan* Gene Expression
Assay Mix and 10 Al of 2 TaqMan Universal PCR Master Mix
(Applied Biosystems). Parallel assays for each sample were carried
out using primers and probes with h-actin for normalization. The
reaction was carried out using the following parameters: 50-C for 2
min, 95-C for 10 min, and 40 cycles of 95-C for 15 s, 60-C for 1
min. Standard curves were prepared for UCHL-1 and for the
endogenous reference h-actin using serial dilutions of control
human brain RNA. Finally, all TaqMan PCR data were captured
using the Sequence Detector Software (SDS version 1.9; Applied
Biosystems).
Gel electrophoresis and Western blotting
Frozen frontal cortex, substantia nigra and medulla oblongata
(100 mg) was directly homogenized in 1 ml lysis buffer (20 mM
HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA,
1 mM DDT, 2 mM PMSF, 1 Ag/ml aprotinin, leupeptin and
pepstatin) and then sonicated. Lysates were centrifuged at 5000
rpm for 10 min at 4-C and protein concentration was determined
with BCA (Pierce) method. 50 Ag of total protein were boiled at
95-C for 3 min and loaded in SDS-polyacrylamide gels with Tris-
glycine running buffer. Proteins were electrophoresed using a mini-
protean system (Bio-Rad) and transferred to nitrocellulose mem-
branes (Bio-Rad) with a Trans-Blot SD Semi-Dry Transfer Cell
Fig. 1. (A) Amplification plot of UCHL-1 using serial dilutions of control
human brain RNA. The horizontal line represents the threshold line
adjusted manually in the exponential phase. The fluorescence intensity
augments with PCR cycles. The number of PCR cycles at which the
fluorescence intensity exceeds the threshold line is defined as the Ct value
on which the relative quantification is based. (B) Representative standard
curves for h-actin and UCHL-1 constructed from several concentrations of
control human brain RNA. Ct values ( y axis) vs. log of several RNA
concentrations of control samples (x axis) show a reverse linear correlation.
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blocked with Tween 20 TBS (TBST) containing 5% skimmed milk
for 30 min. Subsequently, the membranes were incubated at 4-C
overnight with one of the primary antibodies in TBST containing
3% BSA. The following antibodies were used: anti-UCHL-1
(AB5937, Chemicon), anti-UCHL-3 (RB4187, Abgent), anti-h-
actin (clone AC-74, Sigma), anti-proteasome 19Sh (PA1-973,
Affinity BioReagents), anti-proteasome activator 11Sa (PA1-960,
Affinity BioReagents), anti-proteasome 20SX (PA1-977, Affinity
BioReagents) and anti-proteasome 20SY (PA1-978, Affinity
BioReagents). All the antibodies were used at a dilution of 1:500
except for UCHL-3 (1:200) and h-actin (1:5,000). After primary
antibody incubation, the membranes were washed three times with
TBST for 5 min at room temperature, and then incubated with anti-
rabbit or anti-goat IgG antibody labeled with horseradish perox-
idase (Dako) at a dilution of 1:1,000 (1:5,000 for h-actin) for 1 h at
room temperature. Subsequently, the membranes were washed four
times, 5 min each, with TBST at room temperature, and developed
with the chemiluminescence ECL Western blotting system (Amer-
sham/Pharmacia) followed by apposition of the membranes to
autoradiographic films (Hyperfilm ECL, Amersham).
Data analysis
The densitometric quantification of Western Blot bands was
done with the TotalLab v2.01 software. Statgraphics Plus v5
software was used for statistical analysis.
Immunohistochemistry
De-waxed sections 5-Am-thick of the frontal cortex and medulla
oblongata were processed for immunohistochemistry following the
streptavidin LSAB method (Dako). Sections were boiled in citrate
buffer to enhance antigenicity. After incubation with methanol and
H202 in PBS and normal serum, the sections were incubated with
rabbit polyclonal anti-UCHL-1 antibody (Abcam) at a dilution of
1:200. Following incubation with the primary antibody, the
sections were incubated with LASB for 15 min at room
temperature. The peroxidase reaction was visualized with diami-
nobenzidine and H2O2. Control of the immunostaining included
omission of the primary antibody; no signal was obtained
following incubation with only the secondary antibody. Sections
were slightly counterstained with hematoxylin. Cortical sections
from two cases of corticobasal degeneration with large ballooned
neurons in the cerebral cortex were used as a positive control.Results
UCHL-1 mRNA
TaqMan PCR assays were carried out in control and diseased
brains. The ABI Prism 7700 measures the fluorescent accumula-
tion of PCR product by continuous monitoring cycle threshold
(Ct), which is an arbitrary value assigned manually to a level
somewhere above baseline, in the exponential phase of PCR where
there are no rate-limiting components. The Ct value sets the point
at which the sample amplification plot crosses the threshold (Fig.
1A). The analysis of a good reference mRNA is indispensable to
correctly determine mRNA levels. Prior to determining the UCHL-
1 levels, a set of primer combinations of Taqman probes was testedto identify an appropriate control mRNA that displayed minimal
variation between different brain samples. An often used control
(GAPDH) was excluded as both we and others have found that this
mRNA is subject to post-mortem degradation in mRNA samples
(Auer et al., 2003). The h-actin DCt value (Ctcontrol  Ctpathology),
calculated for PD, DLBp and DLBc showed no significant
differences among pathologies (Fig. 2A) and, therefore, h-actin
was chosen as a reference.
For each experimental sample, the amount of target and
endogenous reference was determined from the appropriate
standard curve which was plotted showing the cycle threshold,
Ct (year), versus the log of ng total control RNA (Fig. 1B). Then
the amount of each target UCHL-1 was divided by the endogenous
reference h-actin amount to obtain a normalized target value which
permits determination of the relative mRNA levels of UCHL-1 in
control and in diseased samples.
Decreased UCHL-1 relative mRNA levels were observed in the
cerebral cortex in DLBp and in DLBc when compared with
controls: P < 0.01 for DLBp and P < 0.05 for DLBc, ANOVAwith
post hoc Fisher’s least significant difference (LSD) test (Fig. 2B).
Relative UCHL-1 mRNA levels in the cerebral cortex were not
modified in PD when compared with control values. Reduced
UCHL-1 relative mRNA levels were however observed in the
medulla oblongata in the same PD cases: P < 0.01 (data not
shown).
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UCHL-1 protein levels in the frontal cortex were reduced in
DLBp and DLBc, but not in PD when compared with controls (P <
0.01 for DLBp and P < 0.05 for DLBc, ANOVA with post hoc
LSD test) (Fig. 2C).
Interestingly, UCHL-1 protein levels were reduced in themedulla
oblongata in PD, when compared with controls (P < 0.05, ANOVA
with post hoc LSD test) (Fig. 3A). Similarly, UCHL-1 protein
levels were decreased in diseases with Lewy bodies (Fig. 3B).
Protein decrease was not the result of post-mortem degradation,
as UCHL-1 protein levels were only modified after 22 h in a
paradigm to analyze protein degradation by cumulative delay in the
tissue processing (data not shown).Fig. 2. Relative UCHL-1 gene expression in the frontal cortex of controls
(C, n = 6), Parkinson’s disease (PD, n = 6), Dementia with Lewy bodies,
pure form (DLBp, n = 7) and common form (DLBc, n = 6). (A) DCt values
(mean T SEM) were calculated for h-actin in PD, DLBp and DLBc. (B)
UCHL-1 mRNA levels (mean T SEM) normalized with h-actin. (C) UCHL-
1 protein levels (25 kDa), as detected by Western Blot in total frontal cortex
(area 8) homogenates. h-actin (45 kDa) is blotted to control protein loading.
The image is representative of all the samples indicated in the Table 1,
whereas the densitometric analysis of UCHL-1 protein levels (mean T
SEM) with TotalLab v2.01 software is the result of all the samples included
in the series. UCHL-1 protein values were normalized with h-actin. AU:
arbitrary units. *P < 0.05 and **P < 0.01 compared to control samples
(ANOVA with post hoc LSD test).
Fig. 3. (A) UCHL-1 protein levels are detected in Western blots of total
homogenates of the medulla oblongata of control (C) and Parkinson’s
disease (PD). h-actin (45 kDa) is blotted to control protein loading. The
figure is representative of four control and PD cases. The graphic shows
the densitometric analysis of UCHL-1 protein levels (mean T SEM) with
TotalLab v2.01 software. UCHL-1 protein values are normalized with h-
actin. *P < 0.05 compared to control samples (ANOVA with post hoc
LSD test). (B) UCHL-1 protein levels are detected in Western blots of
total homogenates of the substantia nigra of control (C) and Parkinson’s
disease (PD). h-actin (45 kDa) is blotted to control protein loading. The
figure is representative of four control and Lewy body disease cases. *P <
0.05 compared to control samples (ANOVA with post hoc LSD test).Proteasomal proteins
UCHL-1 down-regulation in DLB was not accompanied by a
decrease in the constitutive levels of the 20SX and 20SY h
subunits of the 26S proteasome, subunit S19h of the 19S complex
and subunit a of the 11S (PA28a) activator (Fig. 4).
UCHL-3 protein
UCHL-3 protein levels in the cerebral cortex were reduced in
PD, DLBp and DLBc when compared with controls (P < 0.001 for
PD, and P < 0.05 for DLBp and DLBc, ANOVA with post hoc
LSD test) (Fig. 5).
Fig. 4. Protein levels of proteasome subunits in the frontal cortex of controls (C, n = 6), Parkinson’s disease (PD, n = 6), Dementia with Lewy bodies, pure form
(DLBp, n = 7) and common form (DLBc, n = 6): h-subunits of the 20S complex, 20SX and 20SY, 19S complex and 11Sa activator. h-actin is blotted to
control protein loading. The image is representative of all the samples indicated in the Table 1. Densitometric analysis of proteasome subunit levels (mean T
SEM) with TotalLab v2.01 software. UCHL-1 protein values were normalized with h-actin. No differences are seen between control, and diseased cases.
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UCHL-1 decorated the cytoplasm of neurons in the cerebral
cortex and medulla oblongata in control and diseased brains. NoFig. 5. UCHL-3 protein levels (26 kDa) are detected in Western blots of total fron
n = 6), Dementia with Lewy bodies, pure form (DLBp, n = 7) and DLB common
The image is representative of all the samples indicated in Table 1. The graphic sho
normalization with h-actin. *P < 0.05, ***P < 0.001 compared to control samplclear reduction of UCHL-1 immunostaining was seen in DLB
cases when compared with controls (data not shown). No differ-
ences were seen in small and large cortical neurons between
control and DLB cases. UCHL-1 was observed equally in neuronstal cortex homogenates in control cases (C, n = 6), Parkinson’s disease (PD,
form (DLBc, n = 6). h-actin (45 kDa) is blotted to control protein loading.
ws the densitometric analysis of UCHL-3 protein levels (mean T SEM) after
es (ANOVA with post hoc LSD test).
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substantia nigra in the substantia nigra and selected nuclei of the
medulla oblongata (data not shown). Lewy bodies and Lewy
neurites were not recognized with the anti-UCHL-1 antibodies here
used, although strong UCHL-1 immunostaining was found in the
cytoplasm of ballooned neurons in two cases of corticobasal
degeneration used as positive controls.Discussion
Abnormal activity of the UPS has been postulated as a crucial
factor in the irregular degradation of a-synuclein leading to the
formation of Lewy bodies and Lewy neurites in PD and related a-
synucleinopathies (McNaught and Olanow, 2003, McNaught et al.,
2003). This is mainly based on the observation of impaired 26S
activity and reduced expression of 20S a-subunits in the substantia
nigra in PD (McNaught and Jenner, 2001; McNaught et al., 2001,
2002b), whereas no changes in 26S activity occur in the cerebral
cortex of PD (McNaught and Olanow, 2003). However, this may
be not the unique mechanism related with the UPS to explain
abnormal a-synuclein degradation. Preserved proteasomal activity
has been noted in the cerebral cortex in DLB and ubiquitination of
a-synuclein is not necessarily associated with impairment of
proteasome function (Tofaris et al., 2003).
UCHL-1 associates with ubiquitin in neuronal cells and
maintains free ubiquitin levels in neurons. Loss of UCHL-1
reduces free ubiquitin, and leads to inadequate ubiquitylation and
protein accumulation in neurons (Osaka et al., 2003). As an
example, inhibition of UCHL-1 in rat ventral mesencephalic
neurons induces intracellular a-synuclein aggregates (McNaught
et al., 2002a). Moreover, UCHL-1 mutation (I93M) reported in
autosomal dominant PD reduces catalytic UPS activity in vitro
(Nishikawa et al., 2003), and is associated with parkinsonism,
cognitive deficits and cortical Lewy pathology (Auburger et al.,
2005). Deletion of exons 7 and 8 of UCHL-1 in mice suffering
from gracile axonal dystrophy is characterized by accumulation of
ubiquitin-positive protein deposits in affected sensory and motor
neurons (Saigoh et al., 1999). Yet UCHL-1 transgenic mice do not
develop a parkinsonian phenotype (Mukoyama et al., 1989; Miura
et al., 1993; Oda et al., 1992; Saigoh et al., 1999; Kurihara et al.,
2001). Together, these observations show abnormal protein
degradation and neuronal degeneration as a result of irregular
UCHL-1 protein targeting, although resulting divergent pheno-
types probably depend on a combination of several conditioning
factors.
The present study has shown reduced UCHL-1 mRNA and
UCHL-1 protein expression in the frontal cortex in DLBp and
DLBc, but not in the frontal cortex in PD. Yet UCHL-1 mRNA and
protein expressions are reduced in the medulla oblongata in the same
PD cases, and UCHL-1 protein levels are reduced in the substantia
nigra in cases with Lewy pathology. Interestingly, reduction of
UCHL-1 mRNA has been recently described in the striatum and
substantia nigra in PD (Miller et al., in press). Such decrease is not
related with degradation of mRNA or protein resulting from post-
mortem delay, as UCHL-1 protein levels are maintained up to 22
h after death in a paradigm of delayed tissue processing mimicking
post-mortem autolytic degradation. These changes are not related
with the presence of AD-related changes, as similar results were
observed in DLB cases with and without neurofibrillary tangles, and
with or without amyloid plaques in the frontal cortex. Finally, thesechanges are probably not the result of cell death as other proteins
including those related with the proteasomal pathway have no
modifications in their expression levels. In contrast, UCHL-1
reduction correlates with the presence of morphologic a-synuclein
aggregates in diseases with Lewy bodies.
UCHL-3, another ubiquitin C-terminal hydrolase ubiquitously
distributed (Kurihara et al., 2000) was also examined for
comparative purposes. Reduced UCHL-3 protein levels have been
found in the frontal cortex in PD as well as in DLB patients.
Therefore, in contrast to UCHL-1, there is no association between
the presence of cortical Lewy bodies and low UCHL-3 expression
levels. In this line, in vitro studies using a crude cell-free system
where a-synuclein was conjugated to histidine-tagged ubiquitin
revealed that the addition of UCHL-3 had little effect, whereas the
addition of UCHL-1 rapidly consumed the a-synuclein-ubiquitin
conjugates and produced a trace amount of free a-synuclein (Liu et
al., 2002). These results are in accordance with our findings and
point out the role of reduced UCHL-1 in the formation of
protofibril-to-fibril/Lewy body transformation.
Interestingly, UCHL-1CHL-3 double-knockout mice display a
more severe axonal and cell body degeneration of the gracile tract
than the observed in simple UCHL-1 transgenic mice (Kurihara et
al., 2001). Since simple UCHL-3 knockout mice do not develop
neurological disease, it has been concluded that UCHL-1 and
UCHL-3 have separate and overlapping functions in the mainte-
nance of neurons within the gracile tract (Kurihara et al., 2001). It
is not known the implication of reduced UCHL-3 expression in
addition to the reduced expression of UCHL-1 in the frontal cortex
in DLB cases.
Reduction of UCHL-1 protein levels in DLB is not accompa-
nied by a decrease in the expression of other components of the
UPS, including subunits 20SX and 20SY, 19S complex and 11Sa
subunit of the PA28 activator, thus indicating selective down-
regulation of UCHL-1 in the DLB cerebral cortex.
Interestingly, UCHL-1 is markedly modified by oxidation in PD
and AD (Choi et al., 2004). As a consequence, irregular UCHL-1
in certain neurodegenerative diseases is the result of multiple
mechanisms, including down-regulation of mRNA induction and
protein expression, and oxidative damage. UCHL-1 may be
sequestered or not by abnormal protein aggregates. Seminal studies
have shown UCHL immunoreactivity in ubiquitinated inclusions
characteristics of human neurodegenerative diseases, including
Lewy bodies (Lowe et al., 1990). However, other studies have
shown no UCHL-1 immunostaining in PD although UCHL-1
immunoreactivity was present in neurons with neurofibrillary
tangles in AD (Choi et al., 2004). The present immunohistochem-
ical studies are in agreement with the later observations showing
no UCHL-1 immunoreactivity in Lewy bodies and Lewy neurites,
but strong UCHL-1 immunoreactivity in the cytoplasm of
ballooned neurons in corticobasal degeneration used here as a
positive control.
In summary, the present study has shown down-regulation of
UCHL-1 in the frontal cortex of cases suffering from DLB, and in
the substantia nigra and medulla oblongata in PD and DLB. Since
UCHL-1 participates in the degradation of proteins via UPS,
abnormal UCHL-1 levels may interfere with normal protein
processing and may contribute to Lewy body formation in DLB
and other Lewy body diseases. Whether additional reduction in
UCHL-3 expression may act as a contributory factor remains to be
elucidated. The present findings point UCHL-1 as a putative
therapeutic target in the treatment of DLB.
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